0001209191-21-060112.txt : 20211008 0001209191-21-060112.hdr.sgml : 20211008 20211008184814 ACCESSION NUMBER: 0001209191-21-060112 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211006 FILED AS OF DATE: 20211008 DATE AS OF CHANGE: 20211008 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: King Andrew James CENTRAL INDEX KEY: 0001823187 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37345 FILM NUMBER: 211316324 MAIL ADDRESS: STREET 1: C/O CHINOOK THERAPEUTICS U.S., INC. STREET 2: 1600 FAIRVIEW AVE. E. CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001435049 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1600 FAIRVIEW AVE E. CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-485-7051 MAIL ADDRESS: STREET 1: 1600 FAIRVIEW AVE E. CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH, INC. DATE OF NAME CHANGE: 20111107 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH DATE OF NAME CHANGE: 20080514 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-10-06 0 0001435049 CHINOOK THERAPEUTICS, INC. KDNY 0001823187 King Andrew James C/O CHINOOK THERAPEUTICS, INC. 1600 FAIRVIEW AVE. E. SEATTLE WA 98102 0 1 0 0 Chief Scientific Officer Common Stock 2021-10-06 4 M 0 10151 A 10151 D Common Stock 2021-10-06 4 F 0 3557 12.3686 D 6594 D Restricted Stock Units (RSU) 2021-10-06 4 M 0 10151 0.00 D 2030-10-05 Common Stock 10151 20304 D Restricted stock units convert into common stock on a one-for-one basis. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date. /s/ Kirk Schumacher, Attorney-in-Fact 2021-10-08